What is the success rate of stem cell therapy for Spinal Cord Injury?
No universal success rate exists. Review injury level, completeness and chronicity, exact product and route, comparator, standard neurological classification, independence and participation outcomes, rehabilitation exposure, serious adverse events and complete follow-up.
What the evidence shows for Spinal Cord Injury
Early trials often focus on feasibility and safety. Interpretation requires exact product, injury level and completeness, time window, route, surgery, rehabilitation dose, comparator, blinded neurological and functional outcomes and long-term tumour, infection and worsening-risk surveillance. The FDA consumer alert states that the promoted regenerative products it addresses are not approved in the United States to treat neurological disorders. Natural recovery and intensive rehabilitation must be separated from product effect.
Am I a candidate? → · Spinal Cord Injury: full overview → · Spinal Cord Injury cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Spinal Cord Injury: cell-therapy evidence and registered trials
- How much does stem cell therapy for Spinal Cord Injury cost? (2026)
- Spinal Cord Injury stem cell therapy — your questions answered (2026)
- Spinal Cord Injury: cell-therapy evidence by therapy class
- MSC vs HSCT for Spinal Cord Injury: what the registries show